Abstract: Methods disclosed herein capitalize on the ability of DNA Structure Specific Recognition Proteins (SSRPs) to bind to genomic lesions formed by chemotherapeutic agents, particularly cisplatin-type agents. Methods are provided for predicting whether an agent that damages DNA will also be cytotoxic, and for predicting whether particular eukaryotic cells will be susceptible to killing by a genotoxic drug. A screening method is provided for identifying new genotoxic drugs that produce SSRP-recognized lesions in DNA. Methods also are provided for sensitizing particular eukaryotic cells to killing by chemotherapeutic agents, particularly cisplatin-type drugs.
Type:
Grant
Filed:
June 2, 1997
Date of Patent:
November 5, 2002
Assignee:
Massachusetts Institute of Technology
Inventors:
Stephen J. Lippard, John M. Essigmann, Brian A. Donahue, Jeffrey H. Toney, Suzanne L. Bruhn, Pieter M. Pil, Steven J. Brown, Patti J. Kellett